Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Exagen Inc. (NASDAQ:XGN) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $12.00.

Several research analysts have weighed in on XGN shares. KeyCorp raised Exagen from a “sector weight” rating to an “overweight” rating and set a $12.00 price objective on the stock in a research report on Wednesday, July 30th. B. Riley started coverage on Exagen in a research report on Thursday, September 11th. They issued a “buy” rating and a $15.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on Exagen from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exagen in a research report on Saturday, September 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Exagen in a research report on Wednesday, July 30th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new position in shares of Exagen during the 1st quarter valued at $25,000. XTX Topco Ltd purchased a new position in shares of Exagen during the 2nd quarter valued at $133,000. Occudo Quantitative Strategies LP purchased a new position in shares of Exagen during the 2nd quarter valued at $138,000. Bridgeway Capital Management LLC lifted its position in shares of Exagen by 10.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after buying an additional 2,600 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in shares of Exagen during the 2nd quarter valued at $217,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Stock Up 0.6%

XGN stock opened at $10.96 on Monday. The stock’s fifty day simple moving average is $9.66 and its two-hundred day simple moving average is $7.32. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 1.06. Exagen has a 1-year low of $2.38 and a 1-year high of $11.17. The stock has a market cap of $241.12 million, a P/E ratio of -12.31 and a beta of 1.54.

Exagen (NASDAQ:XGN) last posted its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) earnings per share for the quarter, hitting the consensus estimate of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.The business had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $16.25 million. Exagen has set its FY 2025 guidance at EPS. Analysts expect that Exagen will post -0.88 EPS for the current year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).